Why IMP Accountability Gaps Are a Common Site-Level Audit Finding

Introduction: The Critical Role of IMP Accountability

Investigational Medicinal Products (IMPs) form the backbone of clinical trials, and their accountability is a cornerstone of regulatory compliance. IMP accountability involves documenting the receipt, storage, dispensing, return, and destruction of trial drugs. Regulators such as the FDA, EMA, and MHRA require that investigator sites maintain complete and accurate IMP accountability records.

Gaps in accountability frequently appear in audit findings at the site level. Missing logs, discrepancies in reconciliation, and inadequate destruction records not only compromise data integrity but also raise concerns about patient safety. These gaps are often categorized as major findings because they undermine both trial validity and regulatory trust.

Regulatory Expectations for IMP Accountability

Authorities outline strict requirements for investigational product accountability:

• Maintain detailed logs of IMP receipt, dispensing, return, and destruction.
• Reconcile dispensed versus returned products at every monitoring visit.
• Store accountability records in the Trial Master File (TMF) for inspection readiness.
• Ensure IMP handling is compliant with GCP and protocol requirements.
• Document IMP accountability discrepancies with corrective actions and CAPA reports.

According to the EU Clinical Trials Register, complete accountability is essential to demonstrate trial integrity and protect participants.

Common Audit Findings on IMP Accountability Gaps

1. Missing IMP Accountability Logs

Auditors frequently find missing or incomplete logs, particularly regarding returns or destruction of unused product.

2. Discrepancies in Reconciliation

Inspectors often note that dispensed versus returned IMP counts do not reconcile, raising concerns about product misuse or loss.

3. Inadequate Documentation of Destruction

Many audits reveal missing or unsigned IMP destruction certificates, making it impossible to verify compliance.

4. Poor Sponsor Oversight

Sponsors are often cited for failing to verify site-level accountability practices during monitoring visits.

Case Study: FDA Inspection on IMP Accountability

During an FDA audit of a Phase II oncology trial, inspectors found multiple discrepancies in IMP accountability logs. The site lacked documentation for the return of unused vials, and destruction certificates were incomplete. The finding was categorized as critical, and the sponsor was required to implement immediate corrective measures before continuing enrollment.

Root Causes of IMP Accountability Gaps

Root cause analysis of IMP accountability findings typically reveals:

• Absence of SOPs defining accountability documentation requirements.
• Inadequate training of site staff on IMP management and reconciliation.
• Poor oversight by sponsors or CRO monitors during site visits.
• Failure to maintain inspection-ready IMP documentation in the TMF.
• Resource constraints at sites leading to incomplete recordkeeping.